Company Overview and News

4
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-10-05 zacks
Making its debut on 02/23/2011, smart beta exchange traded fund SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the market.
0941 EDIV VODAF CHLKF CHL VDMCY IEMG VWO YY

 
DEM: Why I'm Still A Strong Believer In This 4% Yielder

2018-10-03 seekingalpha
Its focus on mature dividend-paying companies has provided valuable downside protection in an unexpectedly bearish market.
EDIV DB IEMG VWO

 
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-09-13 zacks
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the market.
0941 EDIV VODAF CHLKF CHL VDMCY IEMG VWO

 
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-08-21 zacks
A smart beta exchange traded fund, the SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) debuted on 02/23/2011, and offers broad exposure to the Broad Emerging Market ETFs category of the market.
EDIV VODAF VDMCY IEMG MLNX VWO

1
EDIV Vs DVYE: Which Is The Best Way To Play Emerging Markets?

2018-07-20 seekingalpha
EDIV and DVYE are the two most popular ETFs focused on dividend-paying stocks in emerging markets.
STT EDIV LUKZY OGZPY OGZRY INDA DVYE LUKOY LUKFY

5
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-06-27 zacks
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
5347 EDIV TNABY IEMG UMC PETFF TNABF ICHR VWO

 
Are EM ETFs the New Definition of Developed Market Investing?

2018-04-19 zacks
Emerging markets’ (EM) equities had a dream run last year. The rally was prompted by accommodative developed market central banks that kept interest rates low and drove investors toward the relatively high-yielding EM bloc (see all Broad Emerging Market ETFs here).
EDIV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 78463X533